| Budget Amount *help |
¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
Fiscal Year 2019: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2018: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2017: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we investigated the susceptibility of small cell lung cancer (SCLC) to ferroptosis. We identified SLC7A1 (xCT), SLC3A2 (CD98hc), MALT1 and BIRC3 as the markers that were downregulated in SCLC and correlated with susceptibility to ferroptosis. Furthermore, we performed immunostaining of xCT using a human lung cancer tissue sample and confirmed that xCT expression was low in SCLC. The tumor organoids were prepared from the RPM mouse, an animal model of SCLC, to establish a model to evaluate the impact of ferroptosis-inducing cancer therapy. Finally, we conducted a non-clinical study by using the xCT inhibitor and obtained a POC in which the ferroptosis-inducing therapy is effective treatment for SCLC.
|
